GLP-1 medications and PCOS: what the evidence actually shows
GLP-1 medicines can help some adults with PCOS manage weight and metabolic risk, but they are not FDA approved to treat PCOS itself.
Read moreThe Patient Intelligence Desk for GLP-1 News, Research, and Access
The next digest is under review
Weekly briefings only appear here after editorial review and public publish. Until the next edition clears, use the archive for recent GLP-1 signal or start with the current patient guides below.
Current headlines
Understanding Wegovy dosing: a clear guide
Wegovy injection starts at 0.25 mg once weekly and increases every four weeks toward a maintenance dose, with label rules for doses that are not tolerated or are missed.
Read moreWhy Insurers Are Dropping or Changing GLP-1 Coverage in 2026
A plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreMost popular
What “Food Noise” Means and Why GLP-1 Patients Keep Using That Phrase
Across GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 medications and PCOS: what the evidence actually shows
GLP-1 medicines can help some adults with PCOS manage weight and metabolic risk, but they are not FDA approved to treat PCOS itself.
Full analysisOutside Publications We Track for Obesity, Metabolic Health, and GLP-1 Care
We track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Rotating three
Medical journalism with occasional obesity crossover
Medicine Uncovered
Started publishing Oct 2024
Medicine Uncovered is broader medical journalism first and a GLP-1 source second. It is worth tracking when obesity treatment starts crossing into larger reporting questions around medicine, health systems, and public understanding. This is a better fit for readers who want occasional strong reporting than for people looking for a dedicated obesity beat.
Broad physician-creator lens with occasional GLP-1 overlap
Mental Health Movement
Started publishing Jan 2023
Jake Goodman’s publication is mostly about mental health and public-facing medicine, not obesity treatment. It still earns a place here because the GLP-1 pieces are accessible, widely shared, and written for readers who want straightforward answers instead of specialist jargon. Think of it as a general-audience crossover source, not a dedicated obesity desk.
Health-tech and care-model analysis
Massively Better Healthcare
Started publishing Sep 2020
Halle Tecco is especially good at explaining how obesity care gets built, sold, reimbursed, and scaled. If you want to understand telehealth GLP-1 companies, payer pressure, startup behavior, and the business logic behind the care models patients keep running into, this is one of the sharper reads in the category. It is less about day-to-day prescribing and more about the machinery around modern obesity treatment.
What Patients Ask First
Managing Side Effects
Cost + Access
Precision Coverage
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.